Compare Stocks: ALDX, ENTA, TENX, and ZNTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.51 -1.6%	$1.84	$1.07 ▼ $6.18	$90.78M	1.16	2.00 million shs	143,703 shs
ENTA Enanta Pharmaceuticals	$13.23 +2.1%	$13.07	$6.45 ▼ $17.15	$388.07M	0.98	194,507 shs	14,978 shs
TENX Tenax Therapeutics	$13.70 -4.4%	$13.67	$5.78 ▼ $19.40	$364.19M	0.92	710,885 shs	165,890 shs
ZNTL Zentalis Pharmaceuticals	$4.68 +0.6%	$4.25	$1.21 ▼ $6.95	$334.24M	1.92	1.67 million shs	58,368 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-0.65%	-3.47%	-32.60%	-11.05%	-68.19%
ENTA Enanta Pharmaceuticals	+2.78%	+1.73%	-14.30%	-10.57%	+82.14%
TENX Tenax Therapeutics	+4.60%	-11.49%	-7.31%	+14.73%	+130.39%
ZNTL Zentalis Pharmaceuticals	-1.90%	+3.10%	+4.26%	+13.69%	+247.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.51 -1.6%	$1.84	$1.07 ▼ $6.18	$90.78M	1.16	2.00 million shs	143,703 shs
ENTA Enanta Pharmaceuticals	$13.23 +2.1%	$13.07	$6.45 ▼ $17.15	$388.07M	0.98	194,507 shs	14,978 shs
TENX Tenax Therapeutics	$13.70 -4.4%	$13.67	$5.78 ▼ $19.40	$364.19M	0.92	710,885 shs	165,890 shs
ZNTL Zentalis Pharmaceuticals	$4.68 +0.6%	$4.25	$1.21 ▼ $6.95	$334.24M	1.92	1.67 million shs	58,368 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-0.65%	-3.47%	-32.60%	-11.05%	-68.19%
ENTA Enanta Pharmaceuticals	+2.78%	+1.73%	-14.30%	-10.57%	+82.14%
TENX Tenax Therapeutics	+4.60%	-11.49%	-7.31%	+14.73%	+130.39%
ZNTL Zentalis Pharmaceuticals	-1.90%	+3.10%	+4.26%	+13.69%	+247.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	265.45% Upside
ENTA Enanta Pharmaceuticals	2.75	Moderate Buy	$20.29	53.37% Upside
TENX Tenax Therapeutics	2.89	Moderate Buy	$37.67	174.88% Upside
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	44.35% Upside

Current Analyst Ratings Breakdown

Latest ALDX, ENTA, TENX, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	TENX Tenax Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00
7/29/2026	TENX Tenax Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00
7/28/2026	TENX Tenax Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$35.00
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/22/2026	TENX Tenax Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$39.00
7/17/2026	ENTA Enanta Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/6/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	TENX Tenax Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00
6/30/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	TENX Tenax Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
ENTA Enanta Pharmaceuticals	$65.32M	5.89	N/A	N/A	$3.03 per share	4.37
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$10.42 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	4.94	N/A	N/A	$2.99 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.46	N/A	N/A	N/A	N/A	-57.34%	-36.33%	8/6/2026 (Estimated)
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.59	N/A	N/A	N/A	-89.56%	-64.04%	-20.22%	8/10/2026 (Confirmed)
TENX Tenax Therapeutics	-$52.60M	-$1.48	N/A	N/A	N/A	N/A	-63.18%	-58.93%	8/12/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.73	N/A	N/A	N/A	N/A	-53.61%	-40.67%	8/5/2026 (Estimated)

Latest ALDX, ENTA, TENX, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TENX Tenax Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	N/A	N/A	N/A	$16.76 million	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0775	N/A	N/A	N/A	$31.33 million	N/A
8/5/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.45	N/A	N/A	N/A	N/A	N/A
7/31/2026	Q2 2026	TENX Tenax Therapeutics	-$0.3813	-$0.35	+$0.0313	-$0.35	N/A	N/A
5/12/2026	Q1 2026	TENX Tenax Therapeutics	-$0.40	-$0.35	+$0.05	-$0.35	N/A	N/A
5/12/2026	Q1 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.50	-$0.01	-$0.50	N/A	N/A
5/11/2026	Q2 2026	ENTA Enanta Pharmaceuticals	-$0.46	-$0.45	+$0.01	-$0.45	$17.03 million	$17.16 million
5/7/2026	Q1 2026	ALDX Aldeyra Therapeutics	-$0.13	-$0.06	+$0.07	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.72	2.72
ENTA Enanta Pharmaceuticals	N/A	3.84	3.84
TENX Tenax Therapeutics	N/A	14.52	14.52
ZNTL Zentalis Pharmaceuticals	N/A	6.19	6.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ENTA Enanta Pharmaceuticals	94.99%
TENX Tenax Therapeutics	1.67%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
ENTA Enanta Pharmaceuticals	11.48%
TENX Tenax Therapeutics	10.81%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	60.32 million	53.20 million	Optionable
ENTA Enanta Pharmaceuticals	160	29.08 million	25.74 million	Optionable
TENX Tenax Therapeutics	9	26.53 million	23.66 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	71.19 million	68.48 million	Optionable

ALDX, ENTA, TENX, and ZNTL Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3 at 5:00 PM | globenewswire.com

Zentalis Pharmaceuticals (ZNTL) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated at Rodman & Renshaw

July 25, 2026 | americanbankingnews.com

Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

July 23, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

July 22, 2026 | marketbeat.com

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

July 20, 2026 | zacks.com

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

July 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Mizuho

July 17, 2026 | marketbeat.com

Zentalis Pharmaceuticals Insider Trading Activity | NASDAQ:ZNTL | Benzinga

June 30, 2026 | benzinga.com

Zentalis Shareholders Back Directors, Auditors and Executive Pay

June 18, 2026 | tipranks.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026 | globenewswire.com

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum ...

May 21, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

May 21, 2026 | globenewswire.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

May 13, 2026 | globenewswire.com

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

May 12, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

May 5, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

April 21, 2026 | globenewswire.com

Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target

April 20, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at ...

April 18, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALDX, ENTA, TENX, and ZNTL Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.50 -0.03 (-1.63%)

As of 10:28 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Enanta Pharmaceuticals NASDAQ:ENTA

$13.23 +0.28 (+2.14%)

As of 10:28 AM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Tenax Therapeutics NASDAQ:TENX

$13.70 -0.63 (-4.38%)

As of 10:28 AM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$4.68 +0.03 (+0.56%)

As of 10:28 AM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, ENTA, TENX, and ZNTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, ENTA, TENX, and ZNTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, ENTA, TENX, and ZNTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALDX, ENTA, TENX, and ZNTL Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Enanta Pharmaceuticals NASDAQ:ENTA

Tenax Therapeutics NASDAQ:TENX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, ENTA, TENX, and ZNTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, ENTA, TENX, and ZNTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, ENTA, TENX, and ZNTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALDX, ENTA, TENX, and ZNTL Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Enanta Pharmaceuticals NASDAQ:ENTA

Tenax Therapeutics NASDAQ:TENX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools